75 岁及以上男性的前列腺癌筛查在专家组建议后下降了 8 个百分点。
Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation.
机构信息
Department of Health Policy and Management, Emory University, Atlanta, Georgia, USA.
出版信息
Health Aff (Millwood). 2013 Mar;32(3):596-602. doi: 10.1377/hlthaff.2012.0555.
Abstract
In 2008 the US Preventive Services Task Force recommended against screening men ages 75 and older for prostate cancer. Using Medicare Current Beneficiary Survey Access to Care files and linked claims, we compared trends in prostate-specific antigen (PSA) testing rates between men ages 75 and older and men ages 65-74. We estimate that the revised recommendation led to a 7.9-percentage-point decline in annual PSA testing rates over two years among men ages 75 and older. Although 42 percent of men in this age group continue to receive PSA tests, our results highlight the potential of guidelines with negative recommendations to reduce the use of low-value medical care.
摘要
2008 年，美国预防服务工作组建议不为 75 岁及以上男性筛查前列腺癌。利用医疗保险当前受益人调查获得的医疗服务使用情况文件和相关索赔数据，我们比较了 75 岁及以上男性与 65-74 岁男性的前列腺特异性抗原（PSA）检测率的变化趋势。我们估计，这一修订建议导致 75 岁及以上男性的 PSA 检测率在两年内下降了 7.9 个百分点。尽管这一年龄组中有 42%的男性仍在接受 PSA 检测，但我们的研究结果突出表明，带有负面建议的指南有可能减少低价值医疗保健的使用。
相似文献
1
Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation.75 岁及以上男性的前列腺癌筛查在专家组建议后下降了 8 个百分点。
Health Aff (Millwood). 2013 Mar;32(3):596-602. doi: 10.1377/hlthaff.2012.0555.
2
Prostate cancer screening practices in a large, integrated health system: 2007-2014.大型综合医疗系统中的前列腺癌筛查实践：2007 - 2014年
BJU Int. 2017 Aug;120(2):257-264. doi: 10.1111/bju.13793. Epub 2017 Feb 26.
3
Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.美国预防服务工作组发布建议后进行的前列腺特异性抗原检测：基于人群的电子健康数据分析
Cancer Causes Control. 2020 Sep;31(9):861-867. doi: 10.1007/s10552-020-01324-x. Epub 2020 Jun 17.
4
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.2012 年美国预防服务工作组建议不鼓励基于前列腺特异性抗原的前列腺癌筛查后，全国前列腺癌筛查率。
J Clin Oncol. 2015 Aug 1;33(22):2416-23. doi: 10.1200/JCO.2015.61.6532. Epub 2015 Jun 8.
5
Five-year downstream outcomes following prostate-specific antigen screening in older men.老年男性前列腺特异性抗原筛查后的 5 年随访结果。
JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.
6
Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.美国预防服务工作组（USPSTF）发布建议后前列腺癌检测率下降。
J Am Board Fam Med. 2015 Jul-Aug;28(4):491-3. doi: 10.3122/jabfm.2015.04.150062.
7
Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.美国预防服务工作组D级不建议筛查前列腺癌对美国前列腺癌确诊病例的影响。
J Urol. 2015 Dec;194(6):1587-93. doi: 10.1016/j.juro.2015.06.075. Epub 2015 Jun 15.
8
Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.老年男性退伍军人健康管理局中的低价值前列腺癌筛查
J Am Geriatr Soc. 2019 Sep;67(9):1922-1927. doi: 10.1111/jgs.16057. Epub 2019 Jul 5.
9
Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.使用100%的美国德克萨斯州医疗保险公共保险索赔数据，对前列腺特异性抗原筛查率高或低的初级保健提供者所护理的老年男性进行下游检测、治疗和年度直接支付情况：一项回顾性队列研究。
BMC Health Serv Res. 2016 Jan 15;16:17. doi: 10.1186/s12913-016-1265-1.
10
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.前列腺特异性抗原检测的变化与美国预防服务工作组修订的前列腺癌筛查建议有关。
JAMA Oncol. 2022 Jan 1;8(1):41-47. doi: 10.1001/jamaoncol.2021.5143.
引用本文的文献
1
Fee cuts for radiology and low-value imaging.放射科费用削减与低价值影像检查
Int J Health Econ Manag. 2025 Jul 23. doi: 10.1007/s10754-025-09398-3.
2
Time to de-implementation of low-value cancer screening practices: a narrative review.减少低价值癌症筛查实践的时机：一项叙述性综述
BMJ Qual Saf. 2025 Jul 18;34(8):547-555. doi: 10.1136/bmjqs-2025-018558.
3
De-implementing low-value care in cancer care delivery: a systematic review.取消癌症护理中的低价值医疗服务：系统评价。
Implement Sci. 2022 Mar 12;17(1):24. doi: 10.1186/s13012-022-01197-5.
4
Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.美国 65 岁及以上男性中前列腺特异性抗原（PSA）检测的使用：对实践干预的影响。
Cancer Rep (Hoboken). 2021 Aug;4(4):e1352. doi: 10.1002/cnr2.1352. Epub 2021 May 1.
5
A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice?自 2001 年以来，巴西医生在前列腺癌筛查中连续降低 PSA 的使用率。这是好消息还是坏消息？
Int Braz J Urol. 2019 May-Jun;45(3):478-485. doi: 10.1590/S1677-5538.IBJU.2018.0179.
6
Exnovation of Low Value Care: A Decade of Prostate-Specific Antigen Screening Practices.低价值医疗的摒弃：前列腺特异性抗原筛查实践十年。
J Am Geriatr Soc. 2019 Jan;67(1):29-36. doi: 10.1111/jgs.15591. Epub 2018 Oct 6.
7
Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.男性对前列腺癌筛查的看法：定性研究的系统评价
PLoS One. 2017 Nov 28;12(11):e0188258. doi: 10.1371/journal.pone.0188258. eCollection 2017.
8
Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.2004 年至 2013 年美国按社会经济地位和地区划分的前列腺癌发病率和前列腺特异性抗原筛查率趋势。
J Urol. 2018 Mar;199(3):676-682. doi: 10.1016/j.juro.2017.09.103. Epub 2017 Sep 28.
9
Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation.2009年美国预防服务工作组乳腺癌筛查建议修订后乳房X光检查率
Cancer Causes Control. 2017 Jan;28(1):41-48. doi: 10.1007/s10552-016-0835-1. Epub 2016 Dec 26.
10
Trends in prostate biopsy in Ontario, 1992-2014: a cohort study.1992 - 2014年安大略省前列腺活检趋势：一项队列研究
CMAJ Open. 2016 Nov 21;4(4):E698-E705. doi: 10.9778/cmajo.20160079. eCollection 2016 Oct-Dec.
本文引用的文献
1
Declines in prostate cancer incidence after changes in screening recommendations.筛查建议改变后前列腺癌发病率的下降。
Arch Intern Med. 2012 Sep 10;172(16):1267-8. doi: 10.1001/archinternmed.2012.2768.
2
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.2008年美国预防服务工作组建议与前列腺癌筛查率
JAMA. 2012 Apr 25;307(16):1692-4. doi: 10.1001/jama.2012.534.
3
Serious health events and discontinuation of routine cancer screening.严重健康事件与常规癌症筛查的终止。
Med Decis Making. 2012 Jul-Aug;32(4):627-35. doi: 10.1177/0272989X11434600. Epub 2012 Jan 27.
4
Influence of publication of US and European prostate cancer screening trials on PSA testing practices.美国和欧洲前列腺癌筛查试验的发表对 PSA 检测实践的影响。
J Natl Cancer Inst. 2011 Mar 16;103(6):520-3. doi: 10.1093/jnci/djr007. Epub 2011 Feb 28.
5
Multiple clinical practice guidelines for breast and cervical cancer screening: perceptions of US primary care physicians.多项乳腺癌和宫颈癌筛查临床实践指南：美国初级保健医生的看法。
Med Care. 2011 Feb;49(2):139-48. doi: 10.1097/MLR.0b013e318202858e.
6
Cancer screening among patients with advanced cancer.晚期癌症患者的癌症筛查。
JAMA. 2010 Oct 13;304(14):1584-91. doi: 10.1001/jama.2010.1449.
7
Overdiagnosis in cancer.癌症过度诊断。
J Natl Cancer Inst. 2010 May 5;102(9):605-13. doi: 10.1093/jnci/djq099. Epub 2010 Apr 22.
8
Plans to stop cancer screening tests among adults who recently considered screening.针对近期考虑过筛查的成年人停止癌症筛查测试的计划。
J Gen Intern Med. 2010 Aug;25(8):859-64. doi: 10.1007/s11606-010-1346-5. Epub 2010 Apr 21.
9
American Cancer Society guideline for the early detection of prostate cancer: update 2010.美国癌症协会前列腺癌早期检测指南：2010 年更新版。
CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98. doi: 10.3322/caac.20066. Epub 2010 Mar 3.
10
Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).前列腺癌筛查决策：全国医疗决策调查（DECISIONS研究）结果
Arch Intern Med. 2009 Sep 28;169(17):1611-8. doi: 10.1001/archinternmed.2009.262.
Zotero 插件